Clinical Watch: June 2019

July 18, 2019

In this issue of Clinical Watch, we discuss the FDA guidance on biosimilar interchangeability. We suggest criteria for a new gene therapy that is currently the most expensive drug in the world and review real-world costs associated with psychotropic polypharmacy in patients with cancer. Finally, we review claims data to identify asthma patients being treated with a short-acting beta agonist only.

For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacy solutions. 

Previous Article
Recovery Month, Grant Applications, and Building Resources for Recovery
Recovery Month, Grant Applications, and Building Resources for Recovery

Next Article
Conduent’s Recent Leadership Recognition by NelsonHall Makes a Statement: Here’s Why
Conduent’s Recent Leadership Recognition by NelsonHall Makes a Statement: Here’s Why

In a recent press release, Conduent announced it was named an overall leader in NelsonHall’s Advanced Analy...